Increased risk of anti-drug antibodies to a second anti-TNF in patients who developed antibodies to the first anti-TNF

被引：0
|
作者：
Yanai, H. [1 ,2 ]
Amir, S. [2 ]
Biron, I. Avni [1 ,2 ]
Perets, T. Tsadok [1 ,2 ]
Shamir, R. [2 ,3 ]
Dotan, I. [1 ,2 ]
Assa, A. [2 ,3 ]
机构：
[1] Rabin Med Ctr, IBD Ctr, Div Gastroenterol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Schneider Childrens Med Ctr, Inst Gastroenterol Nutr & Liver Dis, Petah Tiqwa, Israel
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P506
引用
收藏
页码：S439 / S439
页数：1
相关论文
共 50 条
  • [21] Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease
    Ha, Christina
    Mathur, Jagrati
    Kornbluth, Asher
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (04) : 497 - 505
  • [22] High level of anti-drug antibodies after intra-articular injection of anti-TNF
    Zufferey, Pascal
    Perreau, Mathieu
    So, Alexander
    RHEUMATOLOGY, 2015, 54 (12) : 2291 - 2292
  • [23] SWITCHING OUT OF CLASS OR TO ANOTHER ANTI-TNF AGENT IS THE BEST STRATEGY FOR CLINICAL EFFICACY AND TREATMENT PERSISTENCE IN IBD PATIENTS WITH ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF
    Anjie, Suzanne I.
    Hanzel, Jurij
    Gecse, Krisztina B.
    D'Haens, Geert
    Brandse, Johannan F.
    GASTROENTEROLOGY, 2023, 164 (06) : S1120 - S1121
  • [24] BARRIERS AGAINST TESTING ANTI-TNF DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN ROUTINE CLINICAL PRACTICE
    Gavan, S. P.
    Daker-White, G.
    Payne, K.
    Barton, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1726 - 1727
  • [25] Anti-TNF antibodies and the ischemic heart
    Frolkis, Inna
    Gurevitch, Jacob
    Yuhas, Yael
    Matsa, Menachem
    Paz, Yosef
    Yakirevich, Vladimir
    Israel Journal of Medical Sciences, 1996, 32 (Suppl):
  • [26] Mucosal Healing with Anti-TNF Antibodies
    Chevaux, Jean-Baptiste
    Vavricka, Stephan R.
    Rogler, Gerhard
    Lakatos, Peter L.
    Schoepfer, Alain
    Peyrin-Biroulet, Laurent
    DIGESTION, 2012, 86 : 16 - 22
  • [27] Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients
    Colman, Ruben J.
    Portocarrero-Castillo, Andrea
    Chona, Deepika
    Hellmann, Jennifer
    Minar, Phillip
    Rosen, Michael J.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (04) : 507 - 515
  • [28] Interest in the addition of azathioprine (AZA) to the switch of anti-TNF in IBD patients in loss of response with undetectable anti-TNF trough levels and anti-drug antibodies: A prospective randomised trial
    Roblin, X.
    Paul, S.
    Boschetti, G.
    Phelip, J. M.
    Del Tedesco, E.
    Berger, A.
    Nancey, S.
    Williet, N.
    Flourie, B.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S414 - S415
  • [29] INTEREST IN THE ADDITION OF AZATHIOPRINE (AZA) TO THE SWITCH OF ANTI-TNF IN IBD PATIENTS IN CLINICAL RELAPSE WITH UNDETECTABLE ANTI-TNF TROUGH LEVELS AND ANTI-DRUG ANTIBODIES: A PROSPECTIVE RANDOMIZED TRIAL
    Roblin, Xavier
    Paul, Stephane
    Nancey, Stephane
    Williet, Nicolas
    Flourie, Bernard
    GASTROENTEROLOGY, 2018, 154 (06) : S84 - S84
  • [30] Utility of Measuring Serum Concentrations of Anti-TNF Agents and Anti-Drug Antibodies in Inflammatory Bowel Disease
    Guerra, Ivan
    Chaparro, Maria
    Bermejo, Fernando
    Gisbert, Javier P.
    CURRENT DRUG METABOLISM, 2011, 12 (06) : 594 - 598
12345